In immuno‐oncology, precise PD‐L1 expression evaluation in NSCLC is crucial for guiding therapy, particularly for PD‐1/PD‐L1 inhibitor treatments.16, 17. The gene discussed is CD274; the disease is non-small cell lung carcinoma.